secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0001062822-24-000062
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon appoints Ivan Cheung to board as Lefkowitz retires after 23 years
-------------------------------------------------------------------------

- Robert J. Lefkowitz, M.D. retires from board effective Dec 2, 2024; no disagreement cited.
- Ivan H. Cheung elected to board effective Dec 2, 2024; will serve on audit committee.
- Cheung is CEO of NextPoint Therapeutics, former chairman & CEO of Eisai Inc. (18 yrs).
- Cheung receives initial option for 186,685 shares vesting over 3 years plus standard director fees.
- Company notes catalyst-rich 2025 and beyond in press release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282224000062/0001062822-24-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282224000062/lxrx-20241119.htm
  HTML page:      https://secwatch.observer/filing/0001062822-24-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer